导致低度血清性卵巢癌的分子变化以及对治疗的影响
Lucy Kelliher1, Roni Yoeli-Bik1, Lisa Schweizer2
1Section of Gynecologic Oncology, University of Chicago Department of Obstetrics and Gynecology, Chicago, Illinois, USA.
概括
低度血清性卵巢癌是一种独特的疾病,需要新的治疗方法. 了解其分子驱动因素,如MAPK通路突变,是开发超越当前化疗选择的向治疗的关键.
科学领域:
- 妇科瘤学 妇科瘤学
- 分子瘤学分子瘤学
- 翻译研究是翻译研究.
背景情况:
- 低度血清性卵巢癌 (LGSC) 现在被认为与高度血清性卵巢癌不同.
- 通常LGSC在晚期出现,经常复发,对标准化疗有耐药性.
- 独特的临床和分子行为需要新的治疗策略.
研究的目的:
- 审查目前对LGSC临床,病理和分子特征的理解.
- 为LGSC.确定潜在的治疗目标和新的研究方向.
- 为了突出由于化疗耐药性而需要向治疗的需要.
主要方法:
- 对LGSC的临床,病理和分子数据的文献综述.
- 分析已知的分子驱动因素,包括激素受体表达和MAPK通路突变.
- 检查新出现的治疗点和正在进行的临床试验.
主要成果:
- 关键的分子驱动因素包括激素受体表达和MAPK通路的改变 (KRAS,BRAF,NRAS,NF1/2,EIF1AX,ERBB2).
- CDKN2A突变表明,循环林依赖性激酶4和6 (CDK4/6) 抑制剂的潜在疗效.
- 其他突变 (USP9X,ARID1A,PIK3CA) 已被确定,但缺乏向治疗.
结论:
- 由于其独特的生物学和耐药性模式,LGSC需要不同的治疗方法.
- 准MAPK路径和CDK4/6为LGSC治疗提供了有前途的途径.
- 对LGSC特有的分子变化的进一步研究对于开发有效疗法至关重要.
相关概念视频
Oogenesis
63.6K
In human women, oogenesis produces one mature egg cell or ovum for every precursor cell that enters meiosis. This process differs in two unique ways from the equivalent procedure of spermatogenesis in males. First, meiotic divisions during oogenesis are asymmetric, meaning that a large oocyte (containing most of the cytoplasm) and minor polar body are produced as a result of meiosis I, and again following meiosis II. Since only oocytes will go on to form embryos if fertilized, this unequal...
63.6K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
Tumor Progression
6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K


